Chiome Bioscience Income Statement

Financials in millions JPY. Fiscal year is January - December.

Millions JPY. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	593.29	780.81	682.46	630.82	712.93
Revenue Growth (YoY)	-24.02%	14.41%	8.19%	-11.52%	48.26%
Cost of Revenue	237.71	347.96	283.87	281.96	290.47
Gross Profit	355.58	432.85	398.6	348.86	422.46
Selling, General & Admin	558.82	526.98	551.86	471.9	444.59
Research & Development	776.54	936.74	1,052	1,136	1,312
Operating Expenses	1,335	1,464	1,604	1,608	1,757
Operating Income	-979.77	-1,031	-1,205	-1,259	-1,334
Interest Expense	-3.16	-2.87	-2.07	-1.32	-1.32
Interest & Investment Income	2.46	0.22	0.02	0.02	0.03
Currency Exchange Gain (Loss)	-0.14	0.92	0.51	-0.57	6.63
Other Non Operating Income (Expenses)	-8.52	13.39	-10.54	16.69	-0.33
EBT Excluding Unusual Items	-989.13	-1,019	-1,217	-1,244	-1,329
Gain (Loss) on Sale of Investments	-	-	-	-	-150
Other Unusual Items	9.59	1.67	2.23	5.98	12.91
Pretax Income	-979.54	-1,018	-1,215	-1,238	-1,466
Income Tax Expense	3.24	3.24	5.01	5.01	13.49
Earnings From Continuing Operations	-982.78	-1,021	-1,220	-1,243	-1,480
Net Income	-982.78	-1,021	-1,220	-1,243	-1,480
Net Income to Common	-982.78	-1,021	-1,220	-1,243	-1,480
Shares Outstanding (Basic)	68	58	50	44	40
Shares Outstanding (Diluted)	68	58	50	44	40
Shares Change (YoY)	16.65%	17.48%	12.64%	9.20%	12.26%
EPS (Basic)	-14.47	-17.54	-24.62	-28.26	-36.74
EPS (Diluted)	-14.47	-17.54	-24.62	-28.26	-36.74
Free Cash Flow	-976.07	-1,001	-1,069	-1,191	-1,131
Free Cash Flow Per Share	-14.38	-17.19	-21.58	-27.08	-28.09
Gross Margin	59.93%	55.44%	58.40%	55.30%	59.26%
Operating Margin	-165.14%	-132.03%	-176.59%	-199.53%	-187.16%
Profit Margin	-165.65%	-130.73%	-178.77%	-197.03%	-207.58%
Free Cash Flow Margin	-164.52%	-128.16%	-156.67%	-188.81%	-158.68%
EBITDA	-976.03	-1,030	-1,204	-1,257	-1,331
EBITDA Margin	-164.51%	-131.88%	-176.41%	-199.29%	-186.75%
D&A For EBITDA	3.74	1.17	1.2	1.48	2.96
EBIT	-979.77	-1,031	-1,205	-1,259	-1,334
EBIT Margin	-165.14%	-132.03%	-176.59%	-199.53%	-187.16%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.